Compare IDEXX Laboratories, Inc. (IDXX) vs Gartner Inc (IT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Gartner Inc — how do they compare? IDEXX Laboratories, Inc. trades at $569.65 (market cap $46.22B), while Gartner Inc trades at $186.93 (market cap $11.83B). The key difference: IDEXX Laboratories, Inc. is far larger — about 3.9× Gartner Inc's market cap, and Gartner Inc is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.
| IDXX | IT | |
|---|---|---|
Market Cap | $46.22B | $11.83B |
Sector | Health | Technology |
52-Week High | $766.68 | $264.09 |
52-Week Low | $526.44 | $125.68 |
Enterprise Value | $47.12B | $13.57B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $570.58, down 4.23% over 24 hours, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $4.27 surpassing the $3.94 expectation. Revenue growth remains robust, supported by a 74.21% ROE and expanding diagnostic offerings. Recent news highlights product expansion, including a dual-species cardiac test, reinforcing its market leadership in veterinary diagnostics.
The outlook is positive, driven by durable competitive advantages and international growth potential. However, elevated valuation multiples and competitive pressures pose risks. Analyst consensus is bullish with a $683.33 price target, suggesting significant upside from current levels, though investors should monitor execution on guidance and macroeconomic headwinds.
Gartner (IT) trades at $179.46, down 7.1% over 24 hours, yet maintains strong fundamentals with a P/E of 16.84 and net income margin of 12%. Recent Q2 2026 earnings beat expectations with EPS of $4.37 versus $3.76 estimated. The stock exhibits a bullish technical signal, supported by positive moving averages, though RSI levels indicate potential overbought conditions. Cash flow trends show operational strength despite a net outflow in 2025.
The outlook remains positive due to consistent earnings beats and raised 2026 guidance, but risks include a shareholder investigation and consulting segment weakness. Analyst consensus is mixed with a $172.80 price target, suggesting cautious optimism amid near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Gartner Inc
Based in Stamford, Conn., Gartner provides independent research and analysis on information technology and other related technology industries. Its research is delivered to clients' desktops in the form of reports, briefings, and updates. Typical clients are chief information officers and other business executives who help plan companies' IT budgets. Gartner also provides consulting services and hosted nearly 80 IT conferences across the globe in 2007.
Read more on IT →
